Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
XNK Therapeutics Appoints Hugo Petit as Chief Financial Officer
XNK Therapeutics today announced the appointment of Hugo Petit as Chief Financial Officer (CFO) and […]
XNK Receives EU Tissue Establishment Certificate
XNK Therapeutics today announced that it has been approved as an EU Tissue Establishment. This […]
XNK Therapeutics Raises SEK 132 Million to Accelerate Growth
XNK Therapeutics AB (“XNK”) today announced it has secured a private placement of SEK 132 million, […]
XNK Therapeutics Appoints Markus Thor as Chief Business Officer
XNK Therapeutics AB today announced the appointment of Markus Thor as Chief Business Officer, effective September 6th. He […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more